Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD

Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD. Method: Pearson correlation coefficients were calculated post hoc for changes from baseline to endpoint in outcomes of one randomized, placebo- and active-controlled trial of lisdexamfetamine (osmotic-release methylphenidate reference) and one of guanfacine extended-release (atomoxetine reference). Results: Changes in ADHD Rating Scale IV (ADHD-RS-IV) total score generally correlated moderately with changes in Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) Achievement and Risk Avoidance (r approximate to .4), but weakly with Resilience, Satisfaction, and Comfort (r approximate to .2); and moderately with Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) total score (r approximate to .5). CHIP-CE:PRF Achievement and Risk Avoidance correlated moderately to strongly with WFIRS-P total score (r approximate to .6). Conclusion: The ADHD-RS-IV, CHIP-CE:PRF, and WFIRS-P capture distinct but interconnected aspects of treatment response in individuals with ADHD.

目的：评估注意缺陷多动障碍（ADHD）儿童和青少年在ADHD症状测量、功能损害以及健康相关生活质量方面与治疗相关的变化之间的关系。方法：对利斯的明（渗透释放型哌甲酯作为参照）的一项随机、安慰剂和活性药物对照试验以及胍法辛缓释剂（托莫西汀作为参照）的一项试验中，从基线到终点的结果变化进行事后皮尔逊相关系数计算。结果：ADHD评定量表IV（ADHD - RS - IV）总分的变化通常与儿童健康和疾病状况量表 - 儿童版：家长报告表（CHIP - CE：PRF）的成就和风险规避中等程度相关（r约为0.4），但与恢复力、满意度和舒适度弱相关（r约为0.2）；与韦斯功能损害评定量表 - 家长版（WFIRS - P）总分中等程度相关（r约为0.5）。CHIP - CE：PRF成就和风险规避与WFIRS - P总分中等至强相关（r约为0.6）。结论：ADHD - RS - IV、CHIP - CE：PRF和WFIRS - P捕捉到了ADHD患者治疗反应中不同但相互关联的方面。